anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention demonstrates the biological function of a newly identified osteoclast-secreted protein. This protein, mim-1, has sequence homology with but is distinct from a previously identified neutrophil chemokine protein. Mim-1 may be a key signaling protein secreted by osteoclasts that regulates recruitment and/or differentiation of osteoblast and osteoclast precursor cells. This protein may also serve to maintain osteoclasts in a relatively inactive state prior to secretion. This mechanism is essential for regulating the mass and structural integrity of bone. This protein or an analog and/or antagonists of this protein will have potential therapeutic potential in the treatment of a variety of pathological bone diseases including osteoporosis and metastatic bone diseases.
According to the inclusion and exclusion criteria, 152 UC patients of the First Affiliated Hospital of the Air Forth Medical University from April 2024 to December 2024 will be included. The PSQI scale was used to evaluate the sleep quality of the enrolled patients, and the overall incidence and severity of sleep disorders in UC patients will be evaluated. According to whether the PSQI score is higher than 5 points, the subjects will be divided into UC with sleep disorder group and the UC without sleep disorder group. By reviewing electronic medical records and questionnaire surveys, general clinical information of the subjects will be collected to analyze the risk factors of sleep disorders in UC patients. Mayo score and fecal calprotectin levels will be used to assess disease activity. The correlation between sleep disorders and disease activity in UC patients will be evaluated. Age-, gender-, and education level-matched healthy controls will be recruited from The First Affiliated Hospital of the Air Forth Medical University from April 2024 to December 2024. Heart rate variability will be measured to evaluate vagal nerve activity. Serum pancreatic peptide, norepinephrine, acetylcholine, and serotonin will be measured to evaluate serum neurotransmitter levels, and resting state functional magnetic resonance imaging will be used to evaluate the brain functional activity area of the subjects. Differences and correlations in autonomic nervous system function between UC with sleep disorder and UC without sleep disorder will be explored. 16s sequencing and metabolomics will be used to analyze changes in gut microbiota and metabolites. The correlation between gut microbiota and metabolites and sleep disorders in UC patients will be explored.
The present invention relates to a novel Chinese medicine compound preparation for treating fatty liver and a preparation method thereof. The novel Chinese medicine compound preparation is prepared from components of the following parts by weight: 2 to 10 parts of hawthorn, 1 to 5 parts of danshen root, 0.5 to 3 parts of leech, 0.5 to 3 parts of lucid ganoderma, 0.5 to 1.5 parts of rhubarb, 0.5 to 1.5 parts of kudzuvine root, 0.5 to 1.5 parts of rhizoma polygonati and 0.2 to 1 part of bupleurum root. The selected components are mixed according to the parts by weight and are decocted by adding water. Medicine liquid obtained by decoction every time is filtered and mixed, and is then decompressed and concentrated into thick paste. The thick paste is dried by vacuum or sprayed and dried, granulated, sieved, and then dried to prepare the Chinese medicine compound preparation for treating fatty liver. The total excellence rate of the Chinese medicine compound preparation can reach 72.58%, and the total effective rate is 90.32%.
Clinical studies of asenapine sublingual tablets in the treatment of schizophrenia and bipolar mania did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Of the approximately 2,250 patients in pre-marketing clinical studies of asenapine sublingual tablets, 1.1% (25) were 65 years of age or over. Multiple factors that might increase the pharmacodynamic response to asenapine sublingual tablets, causing poorer tolerance or orthostasis, could be present in elderly patients, and these patients should be monitored carefully. Based on a pharmacokinetic study in elderly patients, dosage adjustments are not recommended based on age alone [see Clinical Pharmacology (12.3)].   
Elderly patients with dementia-related psychosis treated with asenapine sublingual tablets are at an increased risk of death compared to placebo. Asenapine sublingual tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning].
Risk Summary

Contraceptive hormones and/or metabolites are present in human milk. CHCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see Dosage and Administration (2.2)].  The developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for TYBLUME and any potential adverse effects on the breast-fed child from TYBLUME or from the underlying maternal condition. 

Data 

Small amounts of oral-contraceptive steroids and/or metabolites have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, combination oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk.
A 72-year-old male patient presented to our department complaining of with upper abdominal pain and jaundice. He had a history of a side-to-side pancreaticojejunostomy performed 40 years previously for chronic pancreatitis. A diagnostic workup revealed a tumor 3 cm in size in the pancreatic head as the etiology of the jaundice. Subsequently, the patient was diagnosed with resectable pancreatic cancer. Following two cycles of neoadjuvant chemotherapy, an extended pancreatoduodenectomy was performed because of tumor invasion at the previous pancreaticojejunostomy site. Concurrent portal vein resection and reconstruction were performed. Pathological examination confirmed invasive ductal carcinoma (T2N1M0, Stage IIB). This case highlights the clinical challenges in pancreatic head carcinoma following a side-to-side pancreaticojejunostomy. Although pancreaticojejunostomy is believed to reduce the risk of pancreatic cancer in patients with chronic pancreatitis, clinicians should be aware that, even after this surgery, there is still a chance of developing pancreatic cancer during long-term follow-up.
Amino acis of the formula NH3(CH2CH2)n CH2COOH, (I) (where n is 1 or 2) are prepd. by (a) telomerising ethylene with methyl esters of haloacetic acids of the formula XmCH3-mCOOH3 (II) (where either X is Cl and m is 2 or 3 or X is Br and m is 1) at 100-145 degrees C and an ethylene pressure of 25-40 atom. gauge in the presence of a free radical initiator to produce telemeters of the formula CH3OOC. CH3-mXm-1 (CH2CH2)nX, (III) and, when X is Cl, reducing to (III m=1) (b) reacting with NH3 at 135-140 degrees C or, when X is Br, directly reacting (III) with NH3 at 100 degrees C; (c) in either case, hydrolysing the ammonolysis products at 80-90 degrees C and (d) recovering the products from the hydrolysate by use of a styrene-divinyl benzene sulphocationite resin in the H form. (I) are used for treating functional disorders of the central nervous system and in surgery. They also have use as polymerisation promoters and a intermediates in biochemical syntheses. Process is simple and gives high yields. E.g. gamma-aminobutyric acid is obtd. from methyl bromoacetate.
PURPOSE:To obtain an emulsifier which is stable for a long period of time and gives a flavor etc. by mixing decaglycerine monooleate, monoglyceride organic acid ester and/or enzyme-decomposed lecitin in the emulsification using decaglycerine mono-saturated aliphatic acid ester. CONSTITUTION:In the emulsification of oil in water or alcohol using dacaglycerine mono-saturated aliphatic acid ester, a mixture is used in which one or more kinds of compounds selected from 0.3-1.0 pt.wt. of decaglycerine monooleate, 0.002-0.1 pt.wt. of monoglyceride organic acid ester, and 0.001-0.1 pt.wt. of enzyme-decomposed lecitin are mixed with 1 pt.wt. of dacaglycerine mono-saturated aliphatic acid ester. This emulsifier does not cause a viscosity increase nor turn pasty with the passage of time.
The Artisential laparoscopic instrument is a novel device that allows multi-directional articulation during laparoscopic surgery. There are currently no studies evaluating the efficacy or safety of this device in minimally invasive gynecologic surgery. The investigators aim to compare the efficacy and safety of the Artisential instrument with conventional laparoscopic or robotic instruments.

Patients who are scheduled for a laparoscopic or robotic hysterectomy and/or laparoscopic or robotic sacrocolpopexy will be invited to participate in this study. During the suturing portion of the surgery (either vaginal cuff closure during a hysterectomy, or mesh attachment during a sacrocolpopexy), operating times and safety outcomes will be measured. The approach for vaginal cuff closure will be randomly selected. The approach for mesh attachment suturing will be based on the primary surgical approach (conventional laparoscopy or robotic) and compared to suturing with the Artisential and an internally controlled environment. Therefore, half of the knots placed during a case will be with the Artisential laparoscopic device, and the other half will be placed either with robotic instruments or conventional laparoscopic instruments.
OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicities of high dose yttrium Y 90 monoclonal antibody MN-14 with or without doxorubicin plus peripheral blood stem cell rescue in patients with medullary thyroid cancer. II. Correlate organ and tumor dosimetry with toxicity and antitumor responses in these patients. III. Assess response and duration of response in these patients after this treatment.

OUTLINE: This is a dose escalation study of yttrrium Y 90 monoclonal antibody MN-14 (90Y-MN-14). Patients are stratified by prior doxorubicin (yes vs no). Patients receive filgrastim (G-CSF) subcutaneously (SQ) on days -11 to -7 and undergo leukapheresis on days -8 to -6. If an adequate number of CD34+ cells are not harvested, bone marrow is also collected. Patients receive pretherapy targeting consisting of indium In 111 monoclonal antibody MN-14 (In111-MN-14) on day 0. At least 1 confirmed tumor site must be targeted. Patients receive 90Y-MN-14 IV over 30-45 minutes on day 7. Some patients also receive doxorubicin IV on day 8. PBSC or bone marrow is reinfused on approximately day 7-14. Patients also receive G-CSF SQ or IV until blood counts recover. Cohorts of 3-6 patients receive escalating radiological doses of 90Y-MN-14 until the maximum tolerated dose (MTD) is determined. The MTD is defined as either the dose at which no more than 1 of 6 patients experiences dose limiting toxicity or the threshold radiation doses to lungs, kidneys, and liver. Patients are followed weekly for the first month, monthly for 3 months, then every 6 months for up to 5 years.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for each stratum of this study within 3 years.
Adrenocortical carcinoma (ACC) is an orphan cancer with 35% five-year survival that has been unchanged for last five decades. Patients often present with severe hypercortisolism or with mass effects. The only Food and Drug Administration (FDA)-approved drug for ACC is mitotane, an insecticide derivative, which provides only limited additional months of survival, but with toxicities. Little progress in the field has occurred due to a lack of preclinical models. We recently developed new human ACC in vitro and in vivo research models. We produced the first two new ACC cell lines for the field, CU-ACC1 and CU-ACC2, which we have distributed for global collaborations. In addition, we developed 10 ACC patient-derived xenograft (PDX) and two humanized ACC-PDX models to test new therapeutics and examine the mechanism of mitotane action in combination with immunotherapy. These new preclinical models allow us to identify novel targets and test new therapeutics for our patients with adrenal cancer.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS - Pediatric Use)

If irritation develops, desonide cream or ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of desonide cream or ointment should be discontinued until the infection has been adequately controlled.
The exact mechanism of cardiovascular benefit from SGLT2i continues to be the source of further research. The investigators hypothesize that heart failure patients with LVADs will similarly benefit from the SGLT2i-associated natriuresis and diuresis, which in turn reduces preload. This is further associated with reduced heart failure readmissions and right ventricular failure. Additionally, the animal models indicating reduced cardiac work and remodeling in this population may benefit these patients as one of the goals of LVAD implantation is to reduce cardiac energy expenditure and promote remodeling and recovery in these patients.

This is a prospective, randomized controlled study to assess cardiac benefit of SGLT2i in 40 consecutive patients with heart failure undergoing LVAD implantation. After routine LVAD implantation, patients will be randomized 1:1 to one of two routine care arms: management with an SGLT2i \[empagliflozin 10 milligram (mg) daily or dapagliflozin 10 mg daily, based on formulary coverage\] or no SGLT2i. The patient's treating physician will be able to override randomization assignment if they determine that the assignment is not in the patient's best interest. SGLT2i management (if applicable) and follow-up care will be dictated by routine care. Data will be collected from the subject's medical record for 6 months.
Many health systems are shifting policies to promote greater patient involvement in healthcare delivery. Studies have shown that general medical patients who are more active in their care are more satisfied, more committed, have a better understanding of treatment plans, and experience greater improvements in health and patient-centered outcomes when compared to more passive patients. That being said, studies have found that patients have varying preferences when it comes to decision making. Understanding a patient's decision-making preferences can help physicians meet their expectations and may increase patient satisfaction with the decision-making process.

This awareness of decision-making preferences could be beneficial in treating quality of life conditions. Patients seeking care for pelvic floor disorders make medical decisions aimed toward improving symptoms, function, and quality of life. In a recent study, researchers found that 50% of women preferred active involvement, 45% collaborative and 5% passive. However, patients were 1.56 (95% CI:1.06-2.29) times more likely to report collaborative or passive involvement after their visit (p=0.02) with 40% of patients rating their actual role as active, 48% as collaborative, and 11% as passive. In this study, 37% of women did not experience their preferred level of decision-making. Other studies have similar findings with reported 20-40% discordance between patients' preferred involvement and what was achieved.

Discordance can negatively impact patients' outcomes and experiences of care. Interventions to minimize discordance between patients' preferred and perceived involvement in decision-making may significantly improve their overall experience and satisfaction. One possible intervention is eliciting women's preferred level of involvement in decision making prior to the visit and making this information available to the physician. The current study aims to determine whether physicians' awareness of patients' preferred involvement in decision making prior to their initial urogynecologist visit affects patients' perceived involvement in decision making after their visit.
PURPOSE: To obtain the subject medicinal preparation containing a specific compound such as 17-methylene-1,3,5(10)-estratrien-3-ol. CONSTITUTION: This medicinal preparation contairts a compound of the formula (R1 is H, methyl, tetrahydropyranyl or an acyl; R2 is H or methyl) which has a bit higher affinity for estrogen receptor than that of estradiol and induces cell membrane or blood vessel/lymphatic vessel permeability as compared to estradiol. The daily dose of this compound is 50-150μg for treating menopausal disorders, whil-e for hormone-dependent therapy, 0.15-15μg. Besides, this compound is used as a contraceptive in combination with a gestagen-active hormone (e.g. levonorgestrel) esp. in an orally administrable form containing 50-200μg of this compound and 50-500μg potently active gestagen.
PURPOSE: New onset status epilepticus (NOSE), a subtype of status epilepticus, is a neurological emergency associated with significant morbidity and mortality. This study aimed to analyze the phenotypic spectrum and outcomes of patients presenting with NOSE.
METHODS: This prospective and retrospective descriptive study included patients presenting with NOSE over a 10-year period. Data collected included patient demographics, phenotypic characteristics of SE and its etiology, Status Epilepticus Severity Score (STESS), SE classification Axis-II, and Modified Rankin Scale (mRS) scores at admission and discharge. Functional outcomes and seizure status were assessed at least 6 months post-discharge. Prognostic factors for mortality and the development of epilepsy were also analyzed.
RESULTS: A total of 208 patients were included, with a mean age of 41.97 ± 21.66 years, and a male predominance (57.1 %). Focal to bilateral tonic-clonic seizures were observed in 47.5 % of patients. The etiology was acute symptomatic in 35.57 % and remote symptomatic in 24 %. The median hospital stay was 4 days (range: 2.25-10.75 days). The mortality rate was 26.5 %, and 23 % of patients developed epilepsy with a median follow-up of 9 months. Higher age (≥ 50 years), elevated STESS, ICU admission, use of anesthetic agents, refractory status epilepticus (RSE), and new-onset refractory status epilepticus (NORSE) were significant risk factors for mortality (p<0.05). The development of epilepsy was associated with a higher number of antiseizure medications (ASM) at discharge, ICU admission, use of anesthetic agents, RSE, and NORSE (p<0.05).
CONCLUSION: NOSE is a neurological emergency with a variable etiology and significant long-term consequences. Approximately one-fourth of patients presenting with NOSE died, and another quarter developed epilepsy during a median follow-up of 9 months. Identifying and addressing the predictors of mortality and epilepsy development following NOSE may improve long-term outcomes.
PURPOSE:To prepare a skin cosmetic containing an alpha-hydroxycarboxylic acid and a UV light absorbent and/or a UV light-diffusing agent, and capable of preventing or improving skin inflammation and skin roughness caused by UV rays. CONSTITUTION:This skin cosmetic contains 0.05-20wt.% of a 3-18C alpha- hydroxycarboxylic acid (e.g. sodium lactate) and 0.05-25wt.% of a UV light absorbent (e.g. oxybenzene sulfonic acid) and/or a UV light-diffusing agent (e.g. titanium dioxide fine particles), and further suitably contains a pigment, a perfume, an antiseptic, a surfactant, a pigment, etc. The skin cosmetic is prepared into a preparation such as a lotion, an emulsion, a cream or a pack by conventional methods. One or more kinds of the UV light-absorbing agents and a UV light-diffusing agent are suitably combined and added.
A medicinal liquor treating wind-cold-dampness arthralgia is characterized in that the medicinal liquor comprises the following medicine compositions by weight: 30-50 g of herba ephedrae, 20-25 g of radix angelicae pubescentis, 20-40 g of radix achyranthis bidentatae, 20-40 g of ramulus cinnamomi, 20-40 g of radix glycyrrhizae, 100000 g of liquor, and 1000 g of white sugar. Herba ephedrae possesses the effect of warming and dispersing cold pathogen. Radix angelicae pubescentis possesses the efficacies of treating wind-cold-dampness arthralgia, dispelling wind, overcoming dampness, dispersing cold and relieving pain. Radix achyranthis bidentatae possesses the efficacies of treating waist and knee bone pain, hypertonicity of the limbs and wilting and impediment. Ramulus cinnamomi also is called cinnamon twig, also is capable of dissipating cold and releasing the exterior, warming the meridian and freeing vessels and promoting yang qi generation, and also possesses the efficacies of treating wind-cold exterior symptoms and cold-dampness arthralgia. Radix glycyrrhizae possesses the efficacies of tonifying qi and benefiting spleen, harmonizing the middle and relaxing tension, and coordinating actions of the medicinal materials.